🆕🔥 🟢Review #IJAA
Tissue Pharmacokinetics of Antifungal Drugs
This review examined the clinical data on antifungal tissue PK, revealing substantial variability in drug distribution across agents and tissue compartments #IDXposts
https://t.co/Ja7jPySVXl
Mucormycosis is a rapidly progressive, invasive fungal infection that causes severe disease. The latest epidemiologic data, risk factors, diagnostic strategies, and treatment approaches are discussed in a new review. 👉 https://t.co/FjWD1FcZxe
Early diagnosis and initiation of antifungal therapy significantly reduce mortality among patients with mucormycosis and hematologic cancers, from approximately 80% to 40%. Accurate diagnosis of mucormycosis begins at the bedside with evaluation of symptoms and signs in patients at high risk (seen in figure). Although early symptoms and physical findings in patients with mucormycosis are often nonspecific, they carry important diagnostic significance in patient populations with high risk. Periorbital cellulitis, diplopia, focal palatal necrosis, and necrotic wounds in patients at high risk should cause serious concern for mucormycosis and lead to prompt assessment. Maintaining a high index of suspicion for mucormycosis in such patients can be the impetus for obtaining fluids and tissues for diagnostic analysis, ordering imaging procedures, initiating antifungal therapy, requesting surgical assessment, reversing immunodeficiencies, and correcting metabolic abnormalities.
Learn more in the Review Article “Mucormycosis” by Dimitrios P. Kontoyiannis, MD, ScD, and Thomas J. Walsh, MD, from the University of Texas M.D. Anderson Cancer Center (@MDAndersonNews), Center for Innovative Therapeutics and Diagnostics, and University of Maryland School of Medicine (@UMmedschool): https://t.co/FjWD1FcZxe
Combined serum (1,3)-β-D-Glucan and Oral Wash PCR as a non-invasive diagnostic strategy for early detection of Pneumocystis jirovecii pneumonia: an observational retrospective study
✅ Just Accepted
🔗 https://t.co/DHe49TZ0Is
Paradoxical worsening on olorofim in patients undergoing treatment for invasive fungal diseases - Clinical Microbiology and Infection https://t.co/Tm2QdN71R8
Join Dr Sarah Kuehne’s Journal of Medical Microbiology Seminar this Friday on ‘Bacterial Chat: Anaerobic bacteria in multispecies biofilms'. Register here: https://t.co/C0Px1z4lWD #JMM
Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy | Intensive Care Medicine
Thanks and congrats to Ignacio Martin Loeches and the whole team.
https://t.co/Bv1UYuoKPW
Journal of Medical Microbiology (JMM) is proud to launch Diagnosis of Infectious Disease - a new collection in partnership with @LabMedNews. Edited by @robshorten and Mathew Diggle, browse the full collection here: https://t.co/MHP5mKtc9Q #JMM
🍄 A few #UKFungusDay events for fungus fans in the north of England: Shire Brook Valley — walk, displays & guided fungal foray. Durham Botanic Garden — forays, exhibits & mushroom ID. Yorkshire Fungi Fest – talks, workshops & Mushroom Market
👉 More at https://t.co/YiGRaEJWRU
🌍🦠 Just out! Discover the fascinating world of extremotolerant fungi in "Diversity and Ecology of Fungi from Underexplored and Extreme Environments" – now available as a free PDF or hardcover.
https://t.co/9u47pLvrcQ
#Fungi#Mycology#ExtremeEnvironments